ImmunityBio’s (IBRX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note released on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock.

A number of other research firms also recently commented on IBRX. Piper Sandler upgraded ImmunityBio from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $4.25 to $5.00 in a report on Tuesday, May 20th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a report on Monday, May 12th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, ImmunityBio currently has an average rating of “Buy” and an average price target of $12.25.

ImmunityBio Stock Performance

Shares of IBRX opened at $2.71 on Tuesday. The stock has a fifty day moving average of $2.59 and a two-hundred day moving average of $3.07. The company has a market capitalization of $2.39 billion, a PE ratio of -2.95 and a beta of 0.33. ImmunityBio has a fifty-two week low of $1.83 and a fifty-two week high of $7.63.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The business had revenue of $16.52 million during the quarter, compared to the consensus estimate of $17.50 million. As a group, equities research analysts forecast that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Trading of ImmunityBio

Institutional investors and hedge funds have recently made changes to their positions in the company. Slow Capital Inc. acquired a new stake in shares of ImmunityBio during the 1st quarter worth $30,000. Compound Planning Inc. acquired a new stake in ImmunityBio in the 1st quarter valued at $30,000. Thrive Wealth Management LLC acquired a new stake in ImmunityBio in the 1st quarter valued at $30,000. Stephens Inc. AR acquired a new stake in ImmunityBio in the 4th quarter valued at $26,000. Finally, Xponance Inc. acquired a new stake in ImmunityBio in the 1st quarter valued at $33,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.